Results 101 to 110 of about 2,519,772 (150)

Seladelpar Improves Cholestasis and Pruritus in Obeticholic Acid and Fibrate-experienced Patients With Primary Biliary Cholangitis

With the recent announcement of the withdrawal of obeticholic acid (OCA) in the United States (U.S.), there is a need to transition patients with primary biliary cholangitis (PBC) taking OCA to alternative ...
Qi, Xin, Proehl, Sarah, Levy, Cynthia, Gordon, Stuart C, Crittenden, Daria B, Pratt, Daniel   +5 more
core  

New developments in the treatment of primary biliary cholangitis - role of obeticholic acid.

, 2017
Primary biliary cholangitis (PBC) is a chronic autoimmune cholestatic liver disease that predominantly affects women in early to middle age. It is typically associated with autoantibodies to mitochondrial antigens and results in immune-mediated ...
Kowdley, Kris V, Jhaveri, Manan A
core  

Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. [PDF]

Clin Liver Dis (Hoboken), 2021
Ratziu V.
europepmc   +1 more source

Method for preparing a farnesoid X receptor agonist obeticholic acid from hyodeoxycholic acid

, 2017
The invention relates to a process for prepg. a compd. I in particular obeticholic acid (II) and intermediates suitable for its synthesis. A process for the prepn.
Razzetti, Gabriele, Attolino, Emanuele, IULIANO, ANNA, Graziosi, Renzo, Giannotti, Luca, Iannucci, Grazia, Lucchini, Vittorio   +6 more
core  

Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis. [PDF]

Aliment Pharmacol Ther
Abbas N, Smith R, Lytvyak E, Scaravaglio M, Halliday N, Almahroos A, Eden N, Lloyd-Madden D, Sharma S, Ferguson J, Dyson JK, Thorburn D, Jones D, Montano-Loza AJ, Carbone M, Invernizzi P, Mells G, Culver EL, Trivedi PJ.   +18 more
europepmc   +1 more source

Predictors of serious adverse events and non-response in cirrhotic patients with primary biliary cholangitis treated with obeticholic acid. [PDF]

Liver Int, 2022
De Vincentis A, D'Amato D, Cristoferi L, Gerussi A, Malinverno F, Lleo A, Colapietro F, Marra F, Galli A, Fiorini C, Coco B, Brunetto M, Niro GA, Cotugno R, Saitta C, Cozzolongo R, Losito F, Giannini EG, Labanca S, Marzioni M, Marconi G, Morgando A, Pellicano R, Vanni E, Cazzagon N, Floreani A, Chessa L, Morelli O, Muratori L, Pellicelli A, Pompili M, Ponziani F, Tortora A, Rosina F, Russello M, Cannavò M, Simone L, Storato S, Viganò M, Abenavoli L, D'Antò M, De Gasperi E, Distefano M, Scifo G, Zolfino T, Calvaruso V, Cuccorese G, Palitti VP, Sacco R, Bertino G, Frazzetto E, Alvaro D, Mulinacci G, Palermo A, Scaravaglio M, Terracciani F, Galati G, Ronca V, Zuin M, Claar E, Izzi A, Picardi A, Invernizzi P, Vespasiani-Gentilucci U, Carbone M, on behalf of the Club Epatologi Ospedalieri (CLEO)/Associazione Italiana Gastroenterologi ed Endoscopisti Digestivi Ospedalieri (AIGO) PBC Study Group and, the Italian PBC Registry.   +66 more
europepmc   +1 more source

Obeticholic Acid and Other Farnesoid-X-Receptor (FXR) Agonists in the Treatment of Liver Disorders. [PDF]

Pharmaceuticals (Basel)
Fiorucci S, Urbani G, Distrutti E, Biagioli M.   +3 more
europepmc   +1 more source

Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid. [PDF]

BMJ Open
Dunn S, Evans L, Kennedy C, Wafer R, Moody S, Wolstenhulme F, Burton E, Konkoth AB, Fisher H, Chadwick T, Banham A, Hale F, Christie M, Barclay ST, Dyson J, Smith R, Aithal G, Culver E, Aspinall R, Thorburn D, Heneghan M, Hancock HC, Trivedi P, Mells G, Wason J, Jones DEJ.   +25 more
europepmc   +1 more source

Pharmaco-nutraceutical improvement of the response to obeticholic acid with omega-3 polyunsaturated fatty acids. [PDF]

Biochem J
Lavoie AA, Thérien A, Silva A, Paré E, Ciešlak A, Gagnon W, Desjardins C, Verreault M, Trottier J, Vohl MC, Drouin-Chartier JP, Corbeil J, Caron A, Barbier O.   +13 more
europepmc   +1 more source

Obeticholic acid and ferrostatin-1 differentially ameliorate non-alcoholic steatohepatitis in AMLN diet-fed ob/ob mice. [PDF]

Front Pharmacol, 2022
Li S, Zhuge A, Wang K, Xia J, Wang Q, Han S, Shen J, Li L.   +7 more
europepmc   +1 more source